Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 61, Issue 2, 2005, Pages 103-111

  Valle, M ^a,b   Barbanoj, M J ^a   Donner, A ^c   Izquierdo, I ^d   Herranz, U ^e   Klein, N ^c   Eichler, H G ^c   Muller M ^c   Brunner, M ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ICS   (Spain)

^e Cross Research SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 4 (TRIFLUOROMETHYL)BENZOIC ACID; BENZOIC ACID DERIVATIVE; DRUG METABOLITE; LIVER ENZYME; TRIFLUSAL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID; COMPARTMENT MODEL; CONTROLLED STUDY; DATA ANALYSIS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG ELIMINATION; FEMALE; HEADACHE; HUMAN; LIVER DYSFUNCTION; MALE; NAUSEA; NORMAL HUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; SALICYLATES; SALICYLIC ACIDS;

EID: 18744367545     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0887-0     Document Type: Article

References (29)

1. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21(2):195-218
2. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47(2):425-432
3. Mackenzie IR, Hao C, Munoz DG (1995) Role of microglia in senile plaque formation. Neurobiol Aging 16(5):797-804
4. McNeely W, Goa KL (1998) Triflusal. Drugs 55(6):823-833
5. García Rafanell J, Planas JM, Puig Parellada P (1979) Comparison of the inhibitory effects of acetylsalicylic and triflusal on enzymes related to thrombosis. Arch Int Pharmacodyn Ther 237(2):343-350
6. Rutllant Borrel M, Felez J, Diaz JM, Vicente JM, García Rafanell J (1977) Effect of triflusal (UR-1501) a potential antithrombotic agent, on blood coagulation and platelet antiaggregation in man. Curr Ther Res 22:510-521
7. Domínguez MJ, Vacas H, Saez Y, Olabarria I, Velasco A, Iriarte JA, Forn J (1985) Effects on triflusal with prosthetic heart valves. Clin Ther 7:357-360
8. De La Cruz JP, Pavía J, Bellido I, González MC, Sánchez de la Cuesta F (1988) Platelet antiaggregator effect of triflusal human whole blood. Methods Find Exp Clin Pharmacol 10(4):273-277
9. Bucham A (1992) Advances in cerebral ischemia: experimental approaches. Neurol Clin 10:49-61
10. Fernández de Arriba A, Cavalcanti F, Miralles A, Bayón Y, Alonso M, Merlos M, García-Rafanell J, Forn J (1999) Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol 4:753-761
11. Bayón A, Alonso A, Sánchez Crespo M (1999) 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor B activation. Br J Pharmacol 126:1359-1366
12. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jane F (1991) Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet 16(4):269-273
13. Grasela TH, Sheiner LB (1991) Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 19:25S-36S
14. Beal SL, Sheiner LB (1998) NONMEM users' guides. NONMEM project group. University of California at San Francisco, San Francisco
15. Davidian M, Giltinan DM (1995) Non linear models for repeated measurement data. CRC Press, Boca Raton
16. Sheiner LB, Stanski DR, Vozeh S, Miller R, Ham J (1979) Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371
17. Jonsson EN, Karlsson MO (1999) Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64
18. de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41(10):691-703
19. Acarin L, González B, Castellano B (2001) Triflusal posttreatment inhibits glial nuclear Factor-kB, downregulates the glial response, and is neuroprotective in an exocitotoxic injury model in postnatal brain. Stroke 32:2394-2402
20. Acarin L, González B, Castellano B (2002) Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal exocitotoxic damage. Stroke 23:2499-2505
21. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajja A, Stewart CF (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharm 37(3):195-202
22. Sato S, Kitawa S, Nakajima M, Shimada K, Honda A, Miyazaki H (2001) Assessment of tear concentrations on therapeutic drug monitoring. II. Pharmacokinetic analysis of valproic acid in guinea pig serum, cerebrospinal fluid, and tears. Pharm Res 18(4):500-509
23. Anderson BJ, Holford NHG, Wollard GA, Chan PLS (1998) Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. Br J Clin Pharmacol 46:237-243
24. Rowland M, Tozer TN (1995a) Clinical pharmacokinetics: concepts and applications. Williams & Wilkins, Baltimore, pp 114-116
25. Rowland M, Tozer TN (1995b) Clinical pharmacokinetics: concepts and applications. Williams & Wilkins, Baltimore, pp 140-142
26. Tanaka H, Mizojiri K (1999) Drug-protein binding and bloodbrain barrier permeability. J Pharmacol Exp Ther 288:912-918
27. Cruz-Fernández JM, López-Bescos L, García-Dorado D, López-García Aranda V, Cabades A, Martín-Jadraque L, Velasco JA, Castro-Beiras A, Torres F, Marfil F, Navarro E (2000) Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 21(6):457-465
28. Matias-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A, Melo T, TACIP Investigators (2003) Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. Stroke 34(4):840-848
29. Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiuisi G, Famulari A, Rey R, Bauso-Toselli L, Gori H, Ferrari J, Reich E, TAPIRSS investigators (2004) Triflusal vs aspirin for prevention of cerebral infarction. A randomized stroke study. Neurology 62:1073-1080